Long
Schedule 1 to Schedule 5
Epidiolex' shift to schedule 5 is very bullish to me. More convincing than the approval of Tilray to cross the border for studies. They're definitely one step ahead on everyone utilizing the CBD as a compound. LONG
Note
Entering 169.25Note
GW Pharma to sell $300 million in stock offeringOut for now. Entry later
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.